<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448848</url>
  </required_header>
  <id_info>
    <org_study_id>BCAA</org_study_id>
    <nct_id>NCT03448848</nct_id>
  </id_info>
  <brief_title>Role of Branched-chain Amino Acids Infusion as Adjunct Therapy Post Liver Surgery for Patients in Intensive Care Unit</brief_title>
  <official_title>Role of Branched-chain Amino Acids Infusion as Adjunct Therapy Post Liver Surgery for Patients in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of intravenous BCAAs infusion as adjunct
      therapy post liver surgery in intensive care unit (ICU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled in the study&amp;randomly assigned in a 1:1 manner to receive either
      intravenous (IV) BCAAs in a dose of 0.5-1gm/Kg/day for at least 48hours up to maximum 5 days
      immediately post-operative or placebo (sterile normal saline in a volume equal to the study
      drug).

      All demographic data will be obtained including the patients' age, sex, weight,associated
      co-morbidities (diabetes mellitus &amp; hypertension), the presence of chronic liver disease
      (CLD), Child-Pugh score, Sequential Organ Failure Assessment (SOFA), the type of liver
      surgery, &amp; nutritional status according to nutritional risk screening 2002 (NRS 2002);
      well-nourished if NRS 2002 &lt; 3 while malnourished if NRS 2002 â‰¥ 3 prior BCAAs infusion.

      Vital signs including the heart rate, mean arterial pressure (MAP), central venous pressure
      (CVP), arterial oxygen saturation (SaO2), insulin requirements, urine volume &amp; fluid balance
      will be recorded on admission (day 0), then will be followed up and recorded at regular
      intervals during treatment on 1, 3, 5 &amp;7days.

      Laboratory investigations including the complete blood profile (white blood cells, band%,
      lymphocytes), prothrombin time (PT), liver enzymes; Aspartate aminotransferase (AST), Alanine
      aminotransferase (ALT),serum bilirubin, serum albumin, C-reactive protein (CRP)&amp; kidney
      functions will be recorded at randomization as a baseline (day 0)&amp; will be assessed on day
      0,1, 3, 5 &amp; 7 of the study. Thirty-day survival &amp; infectious morbidity will be followed by
      phone calls to the patient or one of his/her first-degree relatives.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect on liver function tests</measure>
    <time_frame>within one week post liver surgery</time_frame>
    <description>improvement of liver function tests, AsT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect on liver function tests</measure>
    <time_frame>within one week post liver surgery</time_frame>
    <description>improvement of ALT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect on liver function tests</measure>
    <time_frame>within one week post surgery</time_frame>
    <description>Improvement of total bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect on liver function tests</measure>
    <time_frame>within one week post surgery</time_frame>
    <description>improvement of alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect on liver function tests</measure>
    <time_frame>within one week post surgery</time_frame>
    <description>improvement of prothrombin time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Child-Pugh score post-surgery.</measure>
    <time_frame>within one week post surgery</time_frame>
    <description>Improvement with BCAA infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SOFA score post-surgery</measure>
    <time_frame>within one week post surgery</time_frame>
    <description>improvement with BCAA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day infectious morbidity Infectious morbidity</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>occurrence of infections post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non infectious morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>occurrence of hepatic encephalopathy, ruptured esophageal varices, ascites requiring diuretic agent for control, wound dehiscence, intra-abdominal bleeding, intestinal obstruction, renal failure, pleural effusion, need mechanical ventilation, blood sugar control &amp; nutritional status change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay. length of ICU stay, length of hospital stay &amp; 28day mortality. length of ICU stay, length of hospital stay &amp; 28day mortality. length of ICU stay, length of hospital stay &amp; 28day mortality.</measure>
    <time_frame>within two weeks post surgery</time_frame>
    <description>Length of ICU stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay. length of ICU stay, length of hospital stay &amp; 28day mortality. length of ICU stay, length of hospital stay &amp; 28day mortality. length of ICU stay, length of hospital stay &amp; 28day mortality.</measure>
    <time_frame>within two weeks post surgery</time_frame>
    <description>Length of hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 day</time_frame>
    <description>28-day mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Function Post BCAA Infusion</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCAA preparation Intravenous infusion</intervention_name>
    <description>BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug</description>
    <arm_group_label>study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sterile normal saline</intervention_name>
    <description>sterile normal saline in a volume equal to the study drug</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects are adults aged between 18&amp; 75years who are admitted to the ICU of
             National Hepatology &amp; Tropical Medicine Research Institute (NHTMRI) post liver surgery
             e.g. hepatocellular carcinoma, liver hemangioma, hydatid resection, segmentectomy,
             partial hepatectomy as in donor for living donated liver transplant.

        Exclusion Criteria:

          -  if pregnant.

          -  hemodynamic instability requiring circulatory support.

          -  need for dose of BCAAs &gt; 1gm/Kg/day or &lt; 0.5 gm/Kg/day.

          -  severe malnutrition; body mass index (BMI &lt; 16).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eman El-Desoki, Ph D</last_name>
    <phone>01227409501</phone>
    <email>eman18350@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>eman El-Desoki, Ph D</last_name>
    <phone>01152931418</phone>
    <email>eman18350@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHTMRI</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eman El-Desoki, Ph D</last_name>
      <phone>01227409501</phone>
      <email>eman18350@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>Eman Desoki</investigator_full_name>
    <investigator_title>Consultant of Intensive care medicine, Ph D</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

